IPP Bureau
JB Pharma posts Q2 FY25 PAT 16% higher at Rs. 175 Cr
By IPP Bureau - November 07, 2024
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
KIMS to acquire 3,000 beds in next 5 years in Kerala
By IPP Bureau - November 07, 2024
The group plans to establish new hospitals in Kerala developing large health cities in Kochi and Kozhikode
Mitsui Chemicals begins sale of i-TFC luminous II dental material range
By IPP Bureau - November 07, 2024
The new range incorporates a product that also contains the S-PRG filler employed in the Giomer range
Mitsui Chemicals invests in clinical kidney disease drug developer Rege Nephro
By IPP Bureau - November 07, 2024
The company uses iPS cells to develop treatments for diseases relating to the kidney
Max Healthcare posts Q2 FY25 consolidated PAT at Rs. 281.81 Cr
By IPP Bureau - November 07, 2024
Max Healthcare Institute has reported total income of Rs. 1,748.30 crores during the period ended September 30, 2024
Apollo Hospitals reports Q2 FY25 consolidated PAT at Rs. 378.8 Cr
By IPP Bureau - November 07, 2024
Apollo Hospitals Enterprise has reported total income of Rs. 5,627.5 crores during the period ended September 30, 2024
Ichnos Glenmark Innovation to present Phase 1 study of Trispecific ISB 2001 in r/rMM at ASH Annual Meeting
By IPP Bureau - November 07, 2024
ISB 2001 demonstrated a favorable safety and tolerability profile, and an overall response rate (ORR) of 75% in r/r MM
Alembic Pharmaceuticals Q2 FY25 PAT up 12% to Rs. 153 Cr
By IPP Bureau - November 07, 2024
US Generics grew 5% to Rs. 467 Crores for the quarter
Vijaya Diagnostic Centre posts Q2 FY25 PAT at Rs. 41.95 Cr
By IPP Bureau - November 07, 2024
Revenue growth was fueled by higher volumes and contributions from both existing and new centres
RPG Life Sciences posts Q2 FY25 revenue Up by 12% YoY
By IPP Bureau - November 07, 2024
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
Mankind Pharma posts Q2 FY25 PAT up 30% at Rs. 659 Cr
By IPP Bureau - November 06, 2024
Revenue from Operations during Q2 FY25 was Rs. 3,077 crore as compared to Rs. 2,708 crore in Q2 FY24.
Venus Remedies gets approval from Malaysian PIC/S GMP for pre-filled syringe facility
By IPP Bureau - November 06, 2024
The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities
Dr. Reddy's Laboratories posts Q2 FY25 PAT at Rs. 1,255.3 Cr
By IPP Bureau - November 06, 2024
Dr. Reddy's Laboratories has reported total income of Rs. 8,016.2 crores during the period ended September 30, 2024
Pfizer reports Q3 2024 revenue higher by 32% at US$ 17.7 billion
By IPP Bureau - November 06, 2024
Raises 2024 revenue guidance to a range of US$ 61 to US$ 64 billion
